Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic.

To enhance its chances of success, the Emeryville, CA-based company has struck an agreement to work with Lyell Immunopharma, another San Francisco Bay Area biotech. Lyell, which is also working on developing on T-cell therapies to treat cancerous tumors, led Eureka’s new funding round, a Series E financing.

Cell therapies use a patients’ own living T cells, reengineered to better fight cancer. Two CAR-T cell therapies have been approved for… Read more »